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Objective. Testing for high risk human papillomavirus (HR-HPV) is increasing; however due to limitations in
speciﬁcity there remains a need for better triage tests. Research efforts have focused recently on methylation of
human genes which show promise as diagnostic classiﬁers.
Methods. Methylation of 26 genes: APC, CADM1, CCND2, CDH13, CDKN2A, CTNNB1, DAPK1, DPYS, EDNRB,
EPB41L3, ESR1, GSTP1, HIN1, JAM3, LMX1, MAL, MDR1, PAX1, PTGS2, RARB, RASSF1, SLIT2, SOX1, SPARC, TERT and
TWIST1was measured by pyrosequencing in cytology specimens from a pilot set of women with normal or cer-
vical intraepithelial neoplasia grade 3 (CIN3) histology. Six genes were selected for testing in Predictors 1, a col-
poscopy referral study comprising 799 women. The three genes EPB41L3, DPYS andMALwere further tested in a
second colposcopy referral study, Predictors 2, comprising 884 women.Results. The six genes selected from the pilot: EPB41L3, EDNRB, LMX1, DPYS, MAL and CADM1 showed signif-
icantly elevated methylation in CIN2 and CIN3 (CIN2/3) versus ≤CIN1 in Predictors 1 (p b 0.01). Highest meth-
ylation was observed in cancer tissues. EPB41L3methylation was the best single classiﬁer of CIN2/3 in both HR-
HPV positive (p b 0.0001) and negative samples (p = 0.02). Logistic regression modeling showed that other
genes did not add signiﬁcantly to EPB41L3 and in Predictors 2, its classiﬁer value was validated with AUC 0.69
(95% CI 0.65–0.73).
Conclusion. Several methylated genes show promise for detecting CIN2/3 of which EPB41L3 seems the best.
Methylated human gene biomarkers used in combination may be clinically useful for triage of women with
HR-HPV infections.© 2014 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. Introduction
Cervical cancer is the third most common type of cancer in women
worldwide and persistent infection with high-risk human papillomavi-
rus (HR-HPV) is the primary etiological agent of the disease [1,2]. Al-
though HR-HPV infections are very common, only a small proportion
(approximately 10%) become persistent, of which a subset drive the
progression of occult precursors to cervical intraepithelial neoplasiaention, Wolfson Institute of
dicine, Queen Mary University
ax: +44 20 7882 3890.
. Open access under CC BY-NC-ND licengrades 2 and 3 (CIN2/3) and eventually cervical cancer [3]. Due to
high sensitivity, no requirements for preservation of cell morphology
and relatively low costs, HR-HPV testing is becoming the preferred
method for CIN screening. However, as only a fraction of HR-HPV posi-
tive women have clinically relevant lesions, use of cytology as the pri-
mary screening test still predominates. Novel diagnostic biomarkers
with high speciﬁcity are desirable as a compliment to HR-HPV testing.
Development of a simple molecular triage test is particularly awaited
because such a test may be more easily implemented in less developed
countries and in vaginal self-collected specimens, thus leading to con-
siderable reduction in cervical cancer deaths worldwide.
HR-HPV infection is a prerequisite for carcinogenesis but is not sufﬁ-
cient alone. Genetic and epigenetic changes in the host and/or viralse. 
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key molecular changes is likely to reveal biomarkers for use in
cancer prevention programs. DNA methylation has been extensively
investigated as a potential biomarker of human cancers [4]. Carefully
orchestrated, DNA methylation plays a crucial role for activating and
silencing genes during normal development; however, its disruption
contributes to carcinogenesis [5]. In cervical cancer, aberrant methyla-
tion can be detected in cervical smears up to 7 years prior to diagnosis
indicating promise as a biomarker [6]. Although many human genes
exhibit elevated methylation in cervical cancer, an effective testing ap-
proach exploiting these changes for triage of HR-HPV positive women
requires a robust assay that can separate CIN2/3 from≤CIN1with an ad-
equate and consistent differential. Quantitative methylation-speciﬁc
polymerase chain reaction (QMSP) assays for CADM1 and MAL [7–9]
have shown promise as triage tools. Other combination QMSP assays
of genes sets such as EPB41L3, JAM3, TERT, C13ORF18 [10,11], LMX1,
PAX1, SOX1, NKX6-1 [12], and APC, HIN-1, RARB, RASSF1A, and TWIST1
[13] are also of interest. Furthermore, some studies have identiﬁed ele-
vated methylation of single or groups of genes, using different technol-
ogies, in both cytology samples as well as biopsy specimens [14]. In the
current study, we aimed to evaluate methylation of 26 human genes in
cytology samples by pyrosequencing. Genes APC, CADM1, CCND2,
CDH13, CDKN2A, CTNNB1, DAPK1, EPB41L3, ESR1, GSTP1, HIN1, JAM3,
LMX1, MAL, PAX1, PTGS2, RARB, RASSF1, SLIT2, SOX1, SPARC, TERT and
TWIST1were selected as they were part of earlier described promising
QMSP assays or reported as aberrant in at least two separate reports
[7–14]. In addition, genes previously not investigated in cervical cancer:
DPYS, EDNRB andMDR1were included as they showed interesting aber-
rant methylation patterns in other cancers of mucosal tissue [15–17].
Pyrosequencing was chosen as it gives absolute quantiﬁcation of
methylation [18] in contrast to the relative quantiﬁcation obtained by
the most commonly used method QMSP. Our aim was to measure the
methylation levels of a set of promising genes on an absolute scale
and to directly compare their methylation, initially in a selected set of
CIN3 and normal samples. Genes that showed the best potential to
separate CIN3 from normal were tested in Predictors 1 (P1) a large
colposcopy referral population. The ﬁnal goalwas to investigate the per-
formance of the most informative genes in a second large study Predic-
tors 2 (P2) and to assess their potential as future triage biomarkers of
HR-HPV positive women. The results of our investigations may be
regarded as independent validation of the biomarkers by virtue of the
use of different specimens and assays in a separate and independent
laboratory.Material and methods
Patient cohort
Archived patient materials collected in two earlier studies, Predic-
tors 1 (P1) [19] and Predictors 2 (P2) [20] were used for methylation
testing. P1 and P2 comprised 1000 and 1099 women respectively at-
tending colposcopy at Hammersmith or St Mary Hospital in London
UK, during 2005–2007 (P1) or 2007–2009 (P2) because of a cytology
ﬁnding of “mild dyskaryosis or worse”. Women were eligible if they
had been referred as a result of one or more abnormal cervical smears,
were not pregnant, had not been treated previously for CIN, nor had a
hysterectomy. Immediately before colposcopy, cervical specimens
were obtained in PreservCyt transport medium. All analyses were
based on a centrally reviewed histopathology and took the highest
grade of abnormality seen in the biopsy or treatment specimen within
9 months of the initial base-line visit as the ﬁnal diagnosis. The number
of womenwith different histology ﬁndings for P1 and P2 is presented in
Supplemental table S1. 201 patients from P1 were excluded due to
insufﬁcient material for the methylation study. For identiﬁcation of
HR-HPV positive samples, Linear Array (Roche Molecular Systems,Inc., Pleasanton, CA, USA) results for P1 and BD HPV test (BD Diagnos-
tics, Burlington, NC, USA) results for P2 were used.
All women received a patient information sheet explaining the study
and provided written consent. Approvals were obtained from the rele-
vant local research ethics committees.
DNA isolation and bisulﬁte conversion
300 μl of PreservCytwas centrifuged at 13 200 rpm for 2min and the
pellet was resuspended in 200 μl PBS. The genomic DNA was extracted
with QIAamp DNA Mini Kit (Qiagen Inc., Hilden, Germany) following
the spin protocol recommended by the manufacturer except that DNA
was eluted in 60 μl AE buffer. 250 ng of DNA was used in the bisulﬁte
conversion reactions where unmethylated cytosines were converted
to uracil with the EZ DNA methylation kit (Zymo research, Irvine, CA)
according to manufacturer's instructions.
The methylation assays
The methylation assays for APC, CCND2, CDH13, CDKN2A, DAPK1,
DPYS, EDNRB, ESR1, GSTP1, HIN1, MAL, MDR1, PTGS2, RARB, RASSF1,
SLIT2 and TWIST1were previously described [21]. The remaining assays
are presented in Supplemental table S2. All primers were designed
using PyroMark Assay Design software version 2.0.1.15 (Qiagen). The
assays were designed to avoid any overlapping of CpG positions and
aimed to investigate the same CpG positions or those in close proximity
to CpG sites previously investigated for a gene. To provide the internal
control for total bisulﬁte conversion, a non CpG cytosine was included.
Although genes C13ORF18 and NKX6-1 were part of combination
QMSP assays of interest [10] we were not able to design corresponding
pyrosequencing assays due to high CpG density. Polymerase chain reac-
tion (PCR) assays were performed as described in the footnote to Sup-
plemental table 2. The presence of the correct amplicon was
conﬁrmed on Qiaxel (Qiagen) and pyrosequencing was done as previ-
ously described [21]. All runs included standard curves as positive con-
trols, of 0%, 50% and 100% methylated human DNA and a non-template
control.
Data analysis
Mean methylation of the investigated CpG positions, 3–6 per each
gene, was used for all the analyses. Median methylation of genes in
CIN2/3 and ≤CIN1 tissues was compared using the Mann–Whitney U
test. For random selection of 40 samples from P1, a computer random
number generator was used. To account for the high number of genes
analyzed on the initial sample set, the Benjamin and Hochberg step-
up procedure for controlling false discovery rate (FDR) was applied
with an FDR limit of 5% [22]. Any failed assays were excluded from the
analysis. Raw p-values are presented in the text and tables with foot-
notes indicating p-values signiﬁcant at 5% FDR. Spearman's rho correla-
tion coefﬁcient was estimated for methylation levels of the 6 genes in
the entire P1 data set. Each gene was evaluated by receiver operating
characteristics (ROCs) analyses, area under the curve (AUC) was the
main measure used to assess the ability of genes to classify high grade
disease. Methylation data from cancers were excluded from all analysis,
but are presented in the supplemental data. Univariate andmultivariate
analysis was done using logistic regression models and compared by
likelihood ratio (LR) and χ2 statistics. STATA v12 and GraphPad Prism
v5.03 were used for statistical analysis and illustrations.
Results
Methylation of 26 genes in 40 patients from the Pilot Set
Themethylation of 26 genes was measured in the pilot set compris-
ing 20 CIN3 and 20 normal controls, all were HR-HPV positive and
Table 1
Median methylation % and interquartile range (IQR), area under the curve (AUC) and 95%
conﬁdence intervals (CI), andMann–WhitneyU test P values for the 6 top genesmeasured
in the HR-HPV positive P1 specimens, comparing women diagnosed with histological
CIN2/3 to women diagnosed with bCIN1 (includes CIN1 and normal).
GENE bCIN1 CIN2/3 AUC 95%CI Pa
Medianb
(n)c
IQR Medianb
(n)c
IQR
EPB41L3 1.4
(363)
1.0–2.5 3.3
(208)
1.4–7.6 0.73 0.68–0.77 2.8*10−19
EDNRB 1.5
(363)
0.8–2.6 3.3
(208)
1.5–6.1 0.67 0.62–0.72 3.4*10−12
DPYS 4.6
(364)
3.2–5.8 5.4
(208)
4.2–6.6 0.65 0.61–0.70 7.4*10−10
LMX1 3.9
(348)
3.3–4.6 4.6
(193)
3.6–7.1 0.63 0.58–0.68 3.4*10−07
MAL 2.4
(363)
1.6–3.5 3.2
(206)
2.1–4.8 0.62 0.57–0.67 2.8*10−06
CADM1 1.6
(357)
0.9–3.0 2.6
(205)
1.1–5.3 0.58 0.53–0.62 1.1*10−03
a Indicates P values not adjusted for multiple testing, all genes remained signiﬁcantly
associated with CIN2/3 (P b 0.05) at a false discovery rate of 5%.
b Themedians and IQR exclude specimenswhere themethylation assay failed or gave a
value of 0%. The numbers of specimens where methylation was either (failed, or 0%) in
bCIN1 for each of the genes were as follows: EPB41L3 (1, 68); EDNRB (1, 131); DPYS (0,
12); LMX1 (16, 21);MAL (1, 43); CADM1 (7, 211), respectively. For CIN2/3 the values for
failed or 0% methylation were EPB41L3 (0, 12); EDNRB (0, 48); DPYS (0, 0); LMX1 (15,
9);MAL (2, 21); CADM1 (3, 101), respectively.
c n indicates thenumber of specimens of eachhistological category tested for each gene.
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Overall the methylation of genes was low with 14 genes—JAM3, GSTP1,
CDKN2A, APC, HIN1, RARB, RASSF1A, TWIST1, ESR1, CDH13, SPARC,
PTGS2, CTNNB1 and CCND2 showing median methylation ≤1% in both
groups (Supplemental table 3), these were excluded from further con-
sideration. Nine genes: EPB41L3, EDNRB, DPYS, CADM1, LMX1, JAM3,
TERT, PAX1 andMDR1 showed elevated methylation in CIN3 and were
individually signiﬁcant at α= 0.05 (Supplemental table 3). However,
after correction for multiple comparisons, only EPB41L3 (p b 0.0001)
and EDNRB (p = 0.0004) remained signiﬁcant and consequently they
were tested in the entire P1 study. In addition, LMX1 and DPYS showed
relatively highmethylation (3–6%)with good ability to separate normal
from CIN3 with AUC N0.7 (Supplemental Table 3). Thus, these genes
were also investigated in the entire P1 cohort. Additionally, MAL and
CADM1 were tested in the P1 study because these two genes were ex-
tensively evaluated in earlier reports and shown as particularly promis-
ing methylation biomarkers. In total, 6 genes were tested in all
remaining (759) samples available from the P1 cohort.
Methylation of EPB41L3, EDNRB, DPYS, LMX1, CADM1 and MAL in the
P1 study
The methylation of the 6 selected genes was measured in all
available P1 samples and was analyzed separately for 572 HR-HPV pos-
itive (Table 1) and 217 negative samples. The success rates for all the
methylation assays was 97.0–99.9%. In HR-HPV positive patients,
Mann–Whitney U test indicated that methylation was elevated in
CIN2/3 for all 6 genes (p b 0.001). Particularly, EPB41L3 showed theTable 2
Spearman correlation coefﬁcient showing the level of correlation of gene methylation in
P1 specimens.
CADM1 MAL DPYS EDNRB EPB41L3 LMX1
CADM1 1.00
MAL 0.19 1.00
DPYS 0.27 −0.02 1.00
EDNRB 0.26 0.55 0.19 1.00
EPB41L3 0.27 0.45 0.20 0.58 1.00
LMX1 0.26 0.38 0.28 0.42 0.40 1.00best separation of high grade lesions from those with ≤CIN1 with AUC
0.73 (95%CI 0.68–0.77). Although EDNRBwas second best at separating
the diagnostic groups with AUC 0.67 (95%CI 0.62–0.72), its methylation
was also most highly correlated to methylation of EPB41L3 (Table 2).
The AUC for DPYS, LMX1, MAL and CADM1 were 0.65 (95%CI 0.60–
0.69), 0.63 (95%CI 0.58–0.68), 0.62 (95%CI 0.57–0.67) and 0.58 (95%CI
0.53–0.62) respectively. Except for DPYS and MAL, methylation of all
genes showed signiﬁcant correlation to methylation of the other genes
(p b 0.001) (Table 2). A logistic regression model was used to explore
the pairwise predictive power of the methylation of the 6 genes (Sup-
plemental table S3). In a multivariate model with EPB41L3, other
genes did not add substantial information for identifying high grade dis-
ease; however DPYS was the strongest gene among the remaining 5
(Supplemental table S4). Therefore, EPB41L3 and DPYS were selected
for investigation in all HR-HPV positive samples (884) in the P2 cohort.
Although pre-selected due to its high proﬁle in publications, CADM1
performed the poorest amongst the six genes, had the lowest AUC,
medianmethylation (Supplemental Fig. S1), and had the lowest univar-
iate LR-χ2 (Supplemental table S4). CADM1 was therefore excluded
from further testing. MAL was however, taken forward for further
evaluation.
In HR-HPV negative patients, EPB41L3 (p = 0.02) and DPYS
(p = 0.04) showed signiﬁcantly elevated methylation in the
10 CIN2/3 cases while the other genes did not (Fig. 1A).Fig. 1. The distribution of methylation in HR-HPV negative and positive samples. A) Com-
parison of methylation distribution of 6 genes in 207 HR-HPV negative controls (white)
and 10 CIN2/3 (grey) in the P1 study. EPB41L3 (p= 0.023) and DPYS (p= 0.043) showed
elevated methylation in CIN2/3 while CADM1 (p = 0.051),MAL (p = 0.810) and LMX1
(p = 0.177) did not. B) Comparison of EPB41L3, DPYS and MALmethylation distribution
in HR-HPV positive bCIN1 controls (white) and CIN2/3 (grey) from P1 and P2 cohort. Sig-
niﬁcantly elevated methylation was observed in CIN2/3 group for all three genes in both
studies (p b 0.0001). Numbers of patients in each group are available in Supplemental
table S1. For better visualisation of the low methylation results, 2 outliers are not shown,
one at 70% EPB41L3methylation in a normal tissue from P2 and one at 91% DPYSmethyl-
ation in a normal tissue from P1. Whiskers of the boxplot mark the 5th and 95th percen-
tiles, the box 25th percentile, median and 75 percentile, while extreme values are shown
by (•).
Fig. 2. The comparison of ROC curves in P1 and P2 for EPB41L3.
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positive samples
EPB41L3, DPYS andMAL showed a similar distribution of methylation
in≤CIN1 and CIN2/3 in both studies (Fig. 1B). The combinedmethylation
data from all HR-HPV positive P1 and P2 samples stratiﬁed by
histology groups: normal, CIN1, CIN2, CIN3 and cancer is shown in
Supplemental Fig. S1. The methylation in cancer tissues was highest,
followed by CIN3.
Based on the methylation data from the P1 specimens, a cut-off to
reach a minimum of 90% sensitivity was selected for the 3 genes:
EBP41L3=0.9,DPYS=2.7 andMAL=0.5 and then applied to data col-
lected in P2 (Table 3). The AUC for all three genes were reproducible in
the two studies and speciﬁcity and sensitivity at the selected cut-off in-
dicated that all three genes preformed similarly in P1 and P2 (Table 3).
EPB41L3 was the best at separating CIN2/3 while MAL was the poorest
classiﬁer. Furthermore EPB41L3 showed the best ability to identify
CIN2/3 in both the P1 and P2 cohort with similar AUC of 0.73 (95% CI
0.68–0.77) and 0.69 (0.65–0.73) respectively (Fig. 2).
Discussion
The absolute methylation of 26 genes in 20 normal cervical scrapes
compared to 20 scrapes fromwomen diagnosedwith CIN3 showed ele-
vated methylation of EBP41L3, EDNRB, DPYS, CADM1, LMX1, JAM3, TERT,
PAX1 and MDR1 (p b 0.05) (Supplemental table 3). However, after ad-
justment for multiple testing in the pilot, only EPB41L3 and EDNRB
remained signiﬁcant. To further investigate the biomarker potential of
these genes, their methylation as well as DPYS, LMX1, CADM1 andMAL
was measured in specimens from the P1 study. Although methylation
ofMAL did not appear interesting in the initial set of 40, it was investi-
gated in the entire P1 cohort because in combination with CADM1, a
QMSP assay based on these two genes has been repeatedly shown as
promising by a team in the Netherlands [7–9]. Similarly, a different
group from Taiwan suggested [12] a four gene model including LMX1,
SOX1, PAX1, NKX6-1 for a QMSP assay. Although we were not able to
obtain an assay for NKX6-1, out of the remaining 3 genes, LMX1 showed
the best separation of CIN3 from normal tissues (Supplemental table 3)
and therefore was also investigated in the P1 specimens. Overall, the
methylation of the 26 genes was low, with median values less than
10%. For 14 genes median methylation of less than 1% was observed in
CIN3 (Supplemental table 3); with such low methylation values there
is an increased possibility of measurement errors and these genes
were not further investigated, regardless of whether or not they were
previously shown to have interesting potential [13,14]. A possible ex-
planation for the disagreement in results between our study and those
in earlier reports is that the small absolute differences we saw by pyro-
sequencingmay be increased by primer-biased QMSP assayswhich give
data in relative terms. Another possibility is that some of the CpG sites
investigated were different from those previously reported due toTable 3
Univariate analysis of the ability of three human genes to separate≤CIN1 from CIN2/3 in HR-H
each group and study is presented. The AUCs with 95%CI, sensitivity and speciﬁcity in P1 and P
EPB41L3 DPYS
P1 P2 P1
No.a of ≤CIN1 363 535 364
No.b of CIN2/3 208 323 208
AUC 0.73 0.69 0.65
95%CI 0.68–0.77 0.65–0.73 0.61–
Cut-off 0.9 2.7
Sensitivity 90 85 90
Speciﬁcity 31 31 22
a Total number of ≤CIN1 in P1 and P2 was 364 and 545 respectively.
b Total number of CIN2/3 in P1 and P2 was 208 and 330 respectively.assay design requirements. Although in close proximity, methylation
can vary in different CpGs that are part of the same CpG island [23].
DAPK1 is an example where our pyrosequencing assay was approxi-
mately 200 bp downstream of the CpG sitesmost commonly investigat-
ed by other methods. DAPK1 has repeatedly been suggested to have
signiﬁcantly altered methylation in high grade lesions in cancers [14].
Recently, this genewas proposed as a complimentary test to HPVmeth-
ylation assays to provide a comprehensive classiﬁer for identiﬁcation
of CIN2+ by use of the bisulﬁte sequencing method [24]. Although
our assay did not show any differences in DAPK1 methylation
(Supplemental Table 3), pyrosequencing or QMSP are more likely tests
than bisulﬁte sequencing for use in a clinical setting and it is possible
that pyrosequencing assays for EPB41L3 andHPV [25] can provide a sim-
ilar combination test as DAPK1 and HPV.
We included testing of MAL in our study as a pre-selected gene be-
cause of the strong data by QMSP that it is a useful biomarker for
CIN2/3. Although we investigated the same CpGs as in the earlier
QMSP studies MAL did not show any promise as a classiﬁer in our
pyrosequencing-based methylation assay indicating important differ-
ences between the methods used and possibly also samples used. The
current main weakness of the proposed CADM1 and MAL QMSP assay
is that it has not been validated by different groups and in different
study populations.PV positive samples. The number of patients with successful methylation measurement in
2 are compared at a cut-off selected in the P1 study to reach minimum 90% sensitivity.
MAL
P2 P1 P2
541 363 543
330 206 326
0.64 0.62 0.59
0.70 0.61–0.68 0.57–0.67 0.55–0.63
0.5
82 90 94
31 12 6
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relatively large set of candidate human genes for pyrosequencing
methylation assays to triage HR-HPV positive women. However, in P1,
we also assessed the biomarker utility of the genes in HR-HPV negative
women. While, all 6 investigated genes showed signiﬁcantly elevated
methylation in 208 CIN2/3HR-HPV positive samples, elevatedmethyla-
tion was observed only for EPB41L3 and DPYS in the 10 CIN2/3 HR-HPV
negative women (Fig. 1A). This suggests that measurement of methyla-
tion of some genesmight be useful to identify womenwho are at risk of
developing cervical cancer irrespective of HR-HPV status.
A combination of the collected methylation data from both P1
and P2 HR-HPV positive women showed that methylation was several
fold higher in cancers for all investigated genes (Supplemental ﬁg. S1).
Although the optimal cut-off for cancer was not established for
EPB41L3, this assaymay be useful for cancer detectionwith an observed
100% sensitivity and 91% speciﬁcity versus the group of CIN2/3 plus
bCIN1 in the P1 specimens (data not shown). It is noteworthy that
the cut-offs for classiﬁcation of cancers were higher than those of
CIN2/3. This demonstrates that when searching for diagnostic
biomarkers able to distinguish low from high grade precursor lesions,
it is reasonable to exclude the cancers from the analyses to avoid poten-
tial skewing of cut-offs, it appears that virtually all the cancers may be
detected regardless of the best ﬁnal cut-offs chosen to detect the
CIN2/3.
EPB41L3, encoding the DAL-1 protein, was originally identiﬁed as a
down-regulated tumor suppressor in lung adenocarcinoma [26] with
later evidence emerging that its down-regulations may be attributed
to promoter hypermethylation [27]. Loss of DAL-1 and its associated
tumor suppressor activity have also been seen in breast [28], prostate
cancer [29] and meningiomas [30]. To the best of our knowledge,
there are no reports illustrating the expression of DAL-1 in cervical
cancer and taking into consideration its role in other cancers as well
as the aberrant methylation seen in our study and reported by others,
further studies are warranted.
Elevated methylation in HPV16 L1 in CIN2/3 lesions is becoming in-
creasingly evident [31–33]. Recently, we showed that a classiﬁer based
on methylation in HPV16 L1 and L2 may be useful for identifying
women with CIN2/3 [25]. Other HPV types such as HPV18, HPV31 and
HPV45have also shown similar characteristics [24,34,35]. The feasibility
of including EPB41L3 in a QMSP assaywith other genes has already been
shown in cervical scrapes [10] and in cervico-vaginal lavages obtained
by a self-sampling [11]. The potential for success of methylation classi-
ﬁers in self-collected specimens increases their value and could lead to
important improvements in preventing cervical cancer deaths, particu-
larly in less developed regions of the world.
Some limitations of our study are that we used a different assay than
most prior investigators and also thatwe used archived specimens from
women referred to colposcopy. Conversely the limitations also provide
some advantages in that our results are a stronger validation of the
intrinsic value of the identiﬁed biomarkers because the biomarker
diagnostic potential is preferably not limited to just certain assays.
Furthermore, we were able to investigate methylation in a large group
of CIN2+. Another limitation is that our study did not include an assess-
ment of all possible CpG sites in the gene promoters which requires
more powerfulmethods such as directed deep sequencing.With respect
to other potential triage methods for HR-HPV positive women such as
reﬂex cytology, p16 staining and HPV genotyping, our results are quite
modest and the best gene EPB41L3 provided an AUC of 0.69 (Table 3)
in the validation set. Therefore we anticipate the need to improve the
performance of our current gene assay or perhaps to use EPB41L3 in
combination with other biomarkers such as methylation of HPV16 and
other HR-HPV [24,25].
In summary, the measurement of methylation of several human
genes may be considered for assays to separate CIN2/3 from normal
women. Methylation of EPB41L3 was low in the ≤CIN1 group, was
signiﬁcantly elevated in CIN2/3 and was highest in cancers; this genewas the best classiﬁer in the set of genes evaluated here. Our pyrose-
quencing assay using EPB41L3 accurately detected CIN2/3 and cervical
cancers in two different sets of specimens and looks suitable for further
evaluation both alone and in combination with other viral and/or
human genes as a potential molecular approach to triage of HR-HPV
positive women.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2014.02.001.
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